AstraZeneca

conference sponsor

AstraZeneca is a global biopharmaceutical company committed to improving health outcomes through innovation and equitable healthcare access. Their dedication to serving vulnerable communities, including refugees, aligns with our mission of advancing refugee healthcare worldwide.

Our Conference Visit Sponsor

AstraZeneca’s Commitment to Global Health

Founded in 1999, AstraZeneca has become a leader in developing life-changing medicines in oncology, rare diseases, respiratory health, and cardiovascular care. With a presence across Europe, the Americas, Africa, and Asia, the company invests heavily in research, healthcare access, and community well-being.

Supporting Refugees and Vulnerable Populations

AstraZeneca demonstrates its commitment to humanitarian health initiatives through:

British Red Cross Partnership: Supporting communities affected by conflict, including 19,000 refugees in Uganda with sanitation, hygiene, and health information.
Disaster Response: Providing emergency relief in crisis zones, including West Africa and the Democratic Republic of Congo.

Expanding Access to Healthcare for Underserved Populations

AstraZeneca is actively addressing health disparities through a range of global and local initiatives that impact refugees, migrants, and other vulnerable groups:

ACT on Health Equity ($3.5M Pledge, Nov 2024): AstraZeneca has committed $3.5 million to nonprofit organizations across the U.S. to improve access, affordability, and health outcomes for historically underserved communities (source). While not exclusively for refugees, this initiative tackles social determinants of health, including housing, food insecurity, and chronic disease care, all of which directly impact migrant communities.
Community Solutions Challenge ($1.35M, 45 Nonprofits Funded): AstraZeneca has awarded $1.35 million in funding to 45 local and regional nonprofits that develop tailored health solutions. These projects provide critical healthcare screenings, chronic disease support, and cancer care services to at-risk communities, including migrant populations.
National Strategic Collaborations ($2.15M Investment): An additional $2.15 million is being invested into regional health equity programs aimed at reducing healthcare access barriers, increasing early disease detection, and supporting new research and education to promote more inclusive healthcare solutions.
Digital Health & Medical Research: The company is leveraging digital health solutions to improve access to medical expertise, ensuring that healthcare professionals serving displaced populations have access to cutting-edge knowledge and training.
Clinical Trial Diversity: AstraZeneca is committed to improving representation of migrant populations in clinical research, leading to better healthcare outcomes for these communities.

AstraZeneca and the Refugee Health Conference

By sponsoring the Refugee Health Conference, AstraZeneca reinforces its mission to improve healthcare for underserved populations. Their support strengthens our discussions on refugee health challenges, emergency medical response, and equitable healthcare solutions.

We are grateful to AstraZeneca for their sponsorship and for advancing healthcare access for displaced populations. Their support drives our shared goal of improving refugee health worldwide.

Their ongoing investments in community-based care, early disease detection, and digital health tools contribute to long-term improvements in global refugee healthcare access. Through their sponsorship, AstraZeneca helps foster critical discussions, collaborative research, and real-world healthcare solutions for the most vulnerable among us.